💙 Are You Being Heard in Your Kidney Cancer Care?
Past surveys show a record 55% of patients now feel definitely involved in their treatment decisions, yet huge gaps remain globally from 75% in the US to 30% in the Republic of Korea.
YES!! So proud to work with a leader of symptom management @lynnhenrymd on this trial when both of us were @huntsmancancer Exercising makes a huge difference in the lives of prostate cancer patients.
🏃♂️ Can exercise meaningfully reduce fatigue in advanced prostate cancer? The answer appears to be yes.
https://t.co/orAA451n2q
A prospective trial of a personalized exercise program in patients with advanced prostate cancer
A prospective trial evaluated a 12-week structured exercise program for patients with advanced prostate cancer receiving androgen deprivation therapy and experiencing fatigue.
➡️Among 72 evaluable patients, fatigue improved by 5.1 PROMIS T-score points, representing a clinically significant reduction.
➡️ Among 76 patients completing fitness assessments, peak aerobic capacity improved by 3.1 ml/kg/min. Supervised weekly exercise combined with home aerobic and resistance training therefore significantly improved fatigue and physical fitness. #ProstateCancer
@maughanonc, @ggebraelmd, @neerajaiims, @umangtalking@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen@AOmlin@ProfKHerrmann@weoncologists
🏃♂️ Can exercise meaningfully reduce fatigue in advanced prostate cancer? The answer appears to be yes.
https://t.co/orAA451n2q
A prospective trial of a personalized exercise program in patients with advanced prostate cancer
A prospective trial evaluated a 12-week structured exercise program for patients with advanced prostate cancer receiving androgen deprivation therapy and experiencing fatigue.
➡️Among 72 evaluable patients, fatigue improved by 5.1 PROMIS T-score points, representing a clinically significant reduction.
➡️ Among 76 patients completing fitness assessments, peak aerobic capacity improved by 3.1 ml/kg/min. Supervised weekly exercise combined with home aerobic and resistance training therefore significantly improved fatigue and physical fitness. #ProstateCancer
@maughanonc, @ggebraelmd, @neerajaiims, @umangtalking@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen@AOmlin@ProfKHerrmann@weoncologists
Standing room only at the OneOncology Annual Conference state of the union this morning. @OneOncology
I'm proud to be part of a physician-led organization that keeps growing. New this year is a urology-only track, which means more GU-focused partners in the room with us. In bladder, kidney and prostate cancer, the patients who do best usually have the entire care team urologist, rad onc, and a medical oncologist working closely together.
#CommunityOncology #GUonc #Urology
My wife is the type of thoughtful physician I aspire to be
She’s working urgent care tonight and seeing kids who are too sick to go trick-or-treating so she brought them toys to take home in the hopes they don’t feel too left out
Talk about putting care in healthcare ❤️
An effective Board of Directors can shape an organization. @montypal has the vision and leadership to guide and grow ASCO nationally and internationally.
So many incredible folks on this list - many of whom are treasured friends.
To @shilpaonc & @PBarataMD, now running phase III trials and making sea changes in how we treat #genitourinary cancers, congratulations!
To @curijoey, the 2027-2028 @myESMO President, congratulations!
To @GregoryAVidal, who I have exchanged ideas over Lou Malnati's pizza with at many an @ASCO, congratulations!
And to @NazliDizman, what more can I say! Achieving the #FASCO status within your first 3 months as faculty at @DanaFarber isan incredible feat & a sign of what's to come!
Congrats to everyone on this list (@Joshua_Reuss, @ryangentzler, @VjChaudharyMD & everyone else!) & thank you for your commitment to @ASCO!
VOLGA explored short periods of EV (3 cycles) with duvalumab in muscle invasive bladder cancer #ESMO26@NEJM. Results showed EVD was associated with better EFS + OS vs cystectomy alone (0.51 and 0.58 respectively). pCR 40-45% with ctDNA clearance rates of 60%. High rates of adjuvant IO therapy uptake and low rates of neuropathy suggest potential advantages of this approach which focuses the ADC in the neoadjuvant phase. It’s likely to be attractive for patients.
Leaving Madrid w so many good moments #ESMO26@myESMO - brain exploding w data & new trials for our patients, feet sore, heart full after connecting w/ old & new friends across the world. Was an incredibly hard wk w loss of Rachna — we continue the hard & good work.
@OncoAlert
Gorgeous AM in Retiro Park ahead of exciting RCC updates #ESMO26:
🌟final KN564 @DrChoueiri
🌟PROs of RAMPART
🌟CA-IX PET
🌟cabo/atezo in metastatic papillary RCC @maughanonc
🌟EVP in RMC
🌟LACO-Stim CART
🌟KIM-1 @VincentWenxinXu
🌟PDL1 #CARE1
🌟LITESPARK011 QoL @DrDanielHeng
Brilliant talks from @AlbigesL, @KoenvdMijn, @YujiMiura5 & @BraunMDPhD at #ESMO26 highlighting novel therapies for #kidneycancer. Lots of perspective shifting evidence & discussion - I’m walking away with (1) the thought that we could still optimize ADCs for RCC despite multiple failed attempts (need to watch the talk!) and (2) the need to explore “smarter TILs”. @OncoAlert
Rigorous biomarker trials are extremely difficult to design. @AlbigesL is doing it!
Looking forward to seeing the results at a future meeting.
#ESMO26@OncoAlert
In the absence of CNS irAEs I have not previously thought much about it. I think most of us under appreciate the cardiac and neuro consequences of long term inflammation from IO. Agree we should focus more on this.
@CPRT65 Camillo Porta and @sophiemerrick1 for great PRO work and discussion of IO AEs and potential long term side effects.
The possibility of persistent worsening “neurocognitive function” must now be discussed with patients who are engaging with adjuvant IO. ESMO26